The litigation over the fraud perpetrated by Theranos Inc. and its executives is still legally relevant, but another Silicon Valley company and its founder have been indicted over misrepresentations to investors over liquid biopsy technologies that were purported to work with just a few drops of blood. A jury recently convicted Mark Schena, the president of Palo Alto-Calif.-based Arrayit Corp., of defrauding investors and causing false claims to be submitted to federal health programs, another example of how investors can be easily misled by hucksters plying the diagnostics trade.
Biotricity Inc. received more than $240,000 in a grant from the U.S. National Heart, Blood and Lung Institute of the National Institutes of Health to launch a study of a new algorithm to be used with its Bioflux device to assess the risk of stroke in patients with chronic kidney disease (CKD).
Researchers from the Terasaki Institute for Biomedical Innovation (TIBI) in Los Angeles are developing a contact lens that can capture and detect exosomes. These are nanometer-sized vesicles found in bodily secretions which have the potential to be diagnostic cancer biomarkers. The team published its work and findings in August 2022 in Advanced Functional Materials.
For a company that dominates the market for devices designed to improve breathing during sleep, Royal Philips NV has had the devil of time catching its own breath over the last 15 months as it has issued wave after wave of recalls.
Massachusetts Institute of Technology (MIT) engineers in collaboration with South Korean cosmetic giant Amorepacific Corp. have created a chip-free, wireless electronic “skin” for sensing and transmitting vital medical signs minus larger, clunkier chips or batteries in most smartphones. MIT postdoc Jun Min Suh explained any change to the skin’s conditions, such as an accelerated heart rate, affect the sensor’s mechanical vibrations, generating an electrical signal that automatically transmits medial data to the consumer.
Collagen is the most abundant protein in the human body, which would seem to make it an unlikely source for an immunotherapy target. But it is where researchers from Immatics Biotechnologies GmbH and the University of Pennsylvania have found a target that was expressed on stromal cells in a number of different solid tumors, but very rare in normal tissues.
Amylyx Pharmaceuticals Inc.’s amyotrophic lateral sclerosis candidate, AMX-0035, will get a rare second bite at the adcom apple Sept. 7. This time around, the Cambridge, Mass.-based company is looking to improve on its first performance by stressing the survival benefit of its drug.
The U.S. FDA’s formation of the Digital Health Center of Excellence was heralded as a key enabler of digital health technologies, but the news hasn’t necessarily had the expected effect. The agency’s December 2021 draft guidance on the use of digital health technologies to assist in the conduct of clinical trials is still in regulatory drydock.
I-Cordis LLC has been awarded a phase II Small Business Innovation Research (SBIR) grant for US$1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for heart failure with preserved ejection fraction (HFpEF).
Seagen Inc. and University of Minnesota have synthesized compounds and their antibody-drug conjugates (ADCs) comprising humanized monoclonal antibody (MAb) bound to Toll-like receptor 7 (TLR7) or TLR8 agonists through linker reported to be useful for the treatment of cancer.
RSS
